France (FR)

LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study) (2019) Ferone D, Pavel ME, Kunz P, De Herder W, Santoro P, Wegener A, Broberg P, et al. Conference contribution Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe (2019) Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, Aiello M, et al. Journal article Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population (2019) Pavel ME, Broberg P, Caplin M, Ruszniewski P, Strosberg J, Santoro P, Ravasi L, Krenning E Conference contribution Physical mechanisms encoded in photoionization yield from IR+XUV setups (2019) Brabec T, Dinh PM, Gao C, McDonald C, Reinhard PG, Suraud É Journal article Delineating the clinical spectrum due to heterozygous TRAF7 missense mutations: A series of 38 cases (2019) Amiel J, Mishra K, Castilla L, Selmer KK, Barak T, Yang S, Blanco-Sanchez B, et al. Conference contribution Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures (2019) Zweier M, Begemann A, Mcwalter K, Cho MT, Abela L, Banka S, Behring B, et al. Conference contribution Delineation of the clinical phenotype caused by de novo CLTC variants (2019) Sa MJN, Venselaar H, Wiel L, Trimouille A, Lasseaux E, Naudion S, Lacombe D, et al. Conference contribution